Overview

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention (PCI) Study 2

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) on chronic statin therapy. Patients are randomized into two groups: atorvastatin pre-treatment group (80mg atorvastatin seven days before PCI) and control group (PCI without atorvastatin pretreatment, chronic statin treatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Motol
Treatments:
Atorvastatin
Atorvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors